Second, genetic studies in humans have established that loss-of-function variants in SLC22A1 (the gene encoding OCT1), which reduce hepatic uptake of metformin [36], do not impact upon the efficacy of metformin to lower HbA1c in individuals with type 2 diabetes [37, 38]. This evidence concerns the gene SLC22A1 and type 2 diabetes mellitus.